Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12931843 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2LCKMEN1HTTKMT2A | |
| SCHEMBL10330551 | 0.77 | ATR (0.47) | LCKBRD9CISD2ATR | |
| SCHEMBL1057673 | 0.77 | ATR (0.44) | LCKBRD9CISD2CYP2C9CYP2C19 | |
| SCHEMBL31664072 | 0.77 | ATR (0.44) | LCKBRD9CISD2CYP2C9CYP2C19 | |
| SCHEMBL20911612 | 0.76 | LCK (0.38) | LCKBRD9CISD2ATR | |
| SCHEMBL25878585 | 0.76 | KMT2A (0.45) | SMN1; SMN2LCKHTTKMT2AALDH1A1 | |
| SCHEMBL10330552 | 0.74 | ATR (0.41) | LCKMEN1HTTKMT2ABRD9 | |
| SCHEMBL21871197 | 0.73 | CA12 (0.46) | LCK | |
| SCHEMBL25136736 | 0.73 | ATR (0.40) | SMN1; SMN2LCKMEN1HTTKMT2A | |
| SCHEMBL9709748 | 0.73 | KMT2A (0.56) | SMN1; SMN2LCKMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722692-B2 | Compounds and compositions as Syk kinase inhibitors | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | SMN1; SMN2 3577/4885LCK 4/4885MEN1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.